Photoselective Vaporization of the Prostate: Long-Term Outcomes and Safety During 10 Years of Follow-Up
Photoselective Vaporization of the Prostate: Long-Term Outcomes and Safety During 10 Years of Follow-Up
复制标题
DOI：
10.1089/end.2016.0522
复制
发表时间：
2016-12-01
影响因子：
2.7
通讯作者：
Kuromatsu, Isao
中科院分区：
文献类型：
--
作者：
Yamada, Yasushi;Furusawa, Jun;Kuromatsu, Isao
目的：目的：评价选择性前列腺汽化术（PVP）的长期疗效和安全性。患者和方法：2005年4月至2015年12月，共1154例良性前列腺增生患者接受PVP治疗。绿色激光器的类型是80 W的磷酸钛氧钾激光器，后来是120 W的三硼酸锂激光器。术前、术后定期评估国际前列腺症状评分（IPSS）、最大尿流率（Qmax）、排尿后残余尿量（PVR）、前列腺特异性抗原（PSA）水平和前列腺体积。手术后，事件，如第二PVP，经尿道切开，永久性导尿管被定义为restressed.Results：PVP后的平均和中位数的随访时间分别为35.4和24.0个月，分别。最长随访时间为125个月。与术前相比，即使在PVP术后10年，IPSS、生活质量评分和PSA浓度也显著改善;然而，Qmax和PVR在10年时没有改善。5年无复发生存率为93.9%，10年为79.0%。27例PVP后发现前列腺癌，所有发现前列腺癌的患者均存活。PVP术后5年和10年的无癌生存率分别为96.7%和89.4%。结论：我们的数据表明，PVP的疗效可维持10年，但超过10年后可能会下降。PVP也没有促进前列腺癌的进展或恶化预后。
Purpose: To evaluate the long-term outcomes and safety photoselective vaporization of the prostate (PVP).Patients and Methods: From April 2005 to December 2015, a total of 1154 patients with benign prostatic hyperplasia underwent PVP. The type of Green Light laser was an 80W potassium-titanyl-phosphate laser and later a 120W lithium triborate laser. Before and after surgery, the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-voiding volume of residual urine (PVR), prostate-specific antigen (PSA) level, and prostate volume were assessed regularly. After surgery, events such as second PVP, transurethral incision, and permanent urethral catheterization were defined as retreatment.Results: The mean and median periods of follow-up after PVP were 35.4 and 24.0 months, respectively. The maximum duration of follow-up was 125 months. Compared with before surgery, the IPSS, quality of life score, and PSA concentration improved significantly, even at 10 years after PVP; however, Qmax and PVR were not improved at 10 years. The retreatment-free survival rate was 93.9% at 5 years and 79.0% at 10 years. Prostate cancer was found in 27 cases after PVP, and all patients who were found to have prostate cancer remained alive. Prostate cancer-free survival after PVP was 96.7% at 5 years and 89.4% at 10 years.Conclusion: Our data suggest that the efficacy of PVP was maintained for 10 years; however, it may decrease after more than 10 years. PVP also did not promote the progression of or worsen the prognosis of prostate cancer.